XOMA (NASDAQ:XOMA) Cut to Sell at StockNews.com

XOMA (NASDAQ:XOMA) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Monday.

Separately, HC Wainwright lowered their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a research report on Monday.

XOMA Price Performance

XOMA opened at $25.72 on Monday. XOMA has a 12-month low of $19.50 and a 12-month high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $302.98 million, a P/E ratio of -7.39 and a beta of 0.90. The stock has a fifty day moving average of $27.55 and a 200-day moving average of $28.06.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.66 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Equities analysts forecast that XOMA will post -1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after buying an additional 1,138 shares during the period. Barclays PLC lifted its position in XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. State Street Corp boosted its holdings in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the period. Finally, Ellsworth Advisors LLC acquired a new stake in shares of XOMA in the third quarter valued at about $516,000. Institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.